» Articles » PMID: 28767097

Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Aug 3
PMID 28767097
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26 million people suffering from CKD in the United States alone. More patients with CKD die of cardiovascular complications than progress to dialysis. Over 80% of CKD patients have hypertension, which is associated with increased risk of cardiovascular morbidity and mortality. Another common, perhaps underappreciated, feature of CKD is an overactive sympathetic nervous system. This elevation in sympathetic nerve activity (SNA) not only contributes to hypertension but also plays a detrimental role in the progression of CKD independent of any increase in blood pressure. Indeed, high SNA is associated with poor prognosis and increased cardiovascular morbidity and mortality independent of its effect on blood pressure. This brief review will discuss some of the consequences of sympathetic overactivity and highlight some of the potential pathways contributing to chronically elevated SNA in CKD. Mechanisms leading to chronic sympathoexcitation in CKD are complex, multifactorial and to date, not completely understood. Identification of the mechanisms and/or signals leading to sympathetic overactivity in CKD are crucial for development of effective therapeutic targets to reduce the increased cardiovascular risk in this patient group.

Citing Articles

Sympathetic transduction to blood pressure in patients with chronic kidney disease.

Kissell C, Young B, Kaur J, Taherzadeh Z, Mohan P, Vianna L Clin Auton Res. 2024; .

PMID: 39542982 DOI: 10.1007/s10286-024-01084-7.


Cardiovascular Disease in Chronic Kidney Disease: Implications of Cardiorespiratory Fitness, Race, and Sex.

Gollie J, Mahalwar G Rev Cardiovasc Med. 2024; 25(10):365.

PMID: 39484137 PMC: 11522834. DOI: 10.31083/j.rcm2510365.


Comprehensive mapping of sensory and sympathetic innervation of the developing kidney.

NGuetta P, McLarnon S, Tassou A, Geron M, Shirvan S, Hill R Cell Rep. 2024; 43(10):114860.

PMID: 39412983 PMC: 11616766. DOI: 10.1016/j.celrep.2024.114860.


Renal nerves in physiology, pathophysiology and interoception.

Evans L, Dayton A, Osborn J Nat Rev Nephrol. 2024; 21(1):57-69.

PMID: 39363020 DOI: 10.1038/s41581-024-00893-3.


Negative association of serum neurofilament light chain with estimated glomerular filtration rate levels and the impact of gender.

Peng H, Liang Z, Huang B, Zhang S, Yang Y Front Neurol. 2024; 15:1457984.

PMID: 39323436 PMC: 11422151. DOI: 10.3389/fneur.2024.1457984.


References
1.
Davisson R . Physiological genomic analysis of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2003; 285(3):R498-511. DOI: 10.1152/ajpregu.00190.2003. View

2.
Bevan R . Trophic effects of peripheral adrenergic nerves on vascular structure. Hypertension. 1984; 6(6 Pt 2):III19-26. DOI: 10.1161/01.hyp.6.6_pt_2.iii19. View

3.
Simpson P . Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest. 1983; 72(2):732-8. PMC: 1129233. DOI: 10.1172/JCI111023. View

4.
Ye S, Zhong H, Yanamadala V, Campese V . Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002; 15(8):717-24. DOI: 10.1016/s0895-7061(02)02959-x. View

5.
Ligtenberg G, Blankestijn P, Oey P, Klein I, Dijkhorst-Oei L, Boomsma F . Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999; 340(17):1321-8. DOI: 10.1056/NEJM199904293401704. View